Better Therapeutics receives FDA authorization for AspyreRx

Better Therapeutics announced that the FDA authorized AspyreRx, a prescription-only digital therapeutic treatment indicated to provide cognitive behavioral therapy to patients 18 years or older with type 2 diabetes. AspyreRx was reviewed through the FDA’s De Novo pathway and its authorization creates a new class of diabetes digital behavioral therapeutic devices. AspyreRx is expected to launch commercially in Q4 2023.